{
    "nctId": "NCT03623490",
    "briefTitle": "Optimizing the Management of Patients With Oral Therapy",
    "officialTitle": "Optimizing the Management of Patients With Oral Therapy: a Randomized Trial Evaluating the Impact of Management on the Occurrence of Side Effects",
    "overallStatus": "TERMINATED",
    "conditions": "Kidney Cancer, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 101,
    "primaryOutcomeMeasure": "Rate of side effects",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patient over 18 years old.\n2. Men or women with kidney cancer treated with Sutent\u00ae chemotherapy (Cohort 1) according to the following schedule: 42-day course: 28 days of treatment + 14 days of break therapeutic)\n3. Women with breast cancer treated with Xeloda\u00ae (Cohort 2) chemotherapy according to the following schedule: 21-day course: 14 days of treatment + 7 days of therapeutic break).\n4. Patient (e) able to understand French read, write, speak.\n5. Patient who received information about the study.\n6. Written and signed consent.\n7. Affiliation to a social security scheme.\n8. Patient reachable by phone.\n\nExclusion Criteria:\n\n1. Patient under guardianship, curatorship or safeguard of justice.\n2. Patient with severe mental retardation impairing comprehension abilities.\n3. Impossibility of submitting to the medical follow-up of the test.\n4. If hospitalized at the time of inclusion: hospitalization forecast greater than 1 week.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}